| Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis … JM Kocarnik, K Compton, FE Dean, W Fu, BL Gaw, JD Harvey, ... JAMA oncology 8 (3), 420-444, 2022 | 1414 | 2022 |
| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 586 | 2022 |
| Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 D Bryazka, MB Reitsma, MG Griswold, KH Abate, C Abbafati, ... The Lancet 400 (10347), 185-235, 2022 | 347 | 2022 |
| The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 EM Alvarez, LM Force, R Xu, K Compton, D Lu, HJ Henrikson, ... The Lancet Oncology 23 (1), 27-52, 2022 | 165 | 2022 |
| Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019 JR Ledesma, J Ma, A Vongpradith, ER Maddison, A Novotney, MH Biehl, ... The Lancet Infectious Diseases 22 (2), 222-241, 2022 | 115 | 2022 |
| Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019 B Armocida, L Monasta, S Sawyer, F Bustreo, G Segafredo, ... The Lancet Child & Adolescent Health 6 (6), 367-383, 2022 | 112 | 2022 |
| Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases M Nicolò, L Ferro Desideri, A Vagge, CE Traverso Expert opinion on investigational drugs 30 (3), 193-200, 2021 | 108 | 2021 |
| Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019 D Jahagirdar, MK Walters, A Novotney, ED Brewer, TD Frank, A Carter, ... The Lancet HIV 8 (10), e633-e651, 2021 | 103 | 2021 |
| Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer F Barra, G Evangelisti, L Ferro Desideri, S Di Domenico, D Ferraioli, ... Expert opinion on investigational drugs 28 (2), 131-142, 2019 | 103 | 2019 |
| Congenital nasolacrimal duct obstruction (CNLDO): a review A Vagge, L Ferro Desideri, P Nucci, M Serafino, G Giannaccare, A Lembo, ... Diseases 6 (4), 96, 2018 | 98 | 2018 |
| Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the … A Haakenstad, JA Yearwood, N Fullman, C Bintz, K Bienhoff, MR Weaver, ... The Lancet global health 10 (12), e1715-e1743, 2022 | 91 | 2022 |
| Optical coherence tomography angiography in neurodegenerative disorders M Pellegrini, A Vagge, L Ferro Desideri, F Bernabei, G Triolo, ... Journal of clinical medicine 9 (6), 1706, 2020 | 76 | 2020 |
| Prevention of progression in myopia: a systematic review A Vagge, L Ferro Desideri, P Nucci, M Serafino, G Giannaccare, ... Diseases 6 (4), 92, 2018 | 72 | 2018 |
| Blue light filtering ophthalmic lenses: a systematic review A Vagge, L Ferro Desideri, C Del Noce, I Di Mola, D Sindaco, ... Seminars in ophthalmology 36 (7), 541-548, 2021 | 42 | 2021 |
| Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries JC Glasbey, TEF Abbott, A Ademuyiwa, A Adisa, E Alameer, S Alshryda, ... The Lancet 400 (10363), 1607-1617, 2022 | 37 | 2022 |
| Advances in the noninvasive diagnosis of dry eye disease L Di Cello, M Pellegrini, A Vagge, M Borselli, L Ferro Desideri, V Scorcia, ... Applied Sciences 11 (21), 10384, 2021 | 35 | 2021 |
| Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration L Ferro Desideri, F Barra, S Ferrero, CE Traverso, M Nicolò Expert opinion on biological therapy 19 (8), 735-751, 2019 | 35 | 2019 |
| Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis F Barra, LF Desideri, S Ferrero British journal of pharmacology 175 (17), 3626, 2018 | 35 | 2018 |
| Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration L Ferro Desideri, CE Traverso, M Nicolò, MR Munk Pharmaceutics 15 (5), 1413, 2023 | 31 | 2023 |
| The role of atropine in preventing myopia progression: an update A Chierigo, L Ferro Desideri, CE Traverso, A Vagge Pharmaceutics 14 (5), 900, 2022 | 31 | 2022 |
